B
HOWL icon

Bailard’s Werewolf Therapeutics HOWL Stock Holding History

Bailard’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-18,127
Closed -$47.1K – 724
2023
Q1 		$47.1K Buy
+18,127
New +$54K ﹤0.01% 695
2022
Q4 		– Sell
-20,200
Closed -$91K – 742
2022
Q3 		$91K Sell
20,200
-1,000
-5% -$5.43K ﹤0.01% 634
2022
Q2 		$87K Buy
+21,200
New +$96.7K ﹤0.01% 663

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Bailard's HOWL Position: Q2 2023 in Review

Bailard sold out of Werewolf Therapeutics (HOWL) in Q2 2023, closing a stake of 18,127 shares — an estimated $47.1K sold.

Bailard first reported a position in HOWL in Q2 2022 and held it in 3 quarters. The position peaked at $91K in Q3 2022. 36 funds tracked by Wall St. Rank hold HOWL as of Q2 2023.

  • Bailard reported no remaining Werewolf Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bailard sold 18,127 Werewolf Therapeutics shares in Q2 2023, an estimated $47.1K.
  • Bailard first reported a position in Werewolf Therapeutics in Q2 2022 and held it in 3 quarters.
  • Bailard's Werewolf Therapeutics position peaked at $91K in Q3 2022.
  • 36 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2023.

Based on Bailard's 13F filing for Q2 2023, filed 20 Jul 2023.